肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：CPI-613联合大剂量阿糖胞苷和米托蒽醌治疗复发或耐药急性髓系白血病

2018-05-09 MedSci MedSci原创

急性髓系白血病CPI-613阿糖胞苷米托蒽醌
关注

CPI-613可以抑制PDH和α-KGDH，在髓系恶性疾病中具有治疗活性。CLIN CANCER RES近期发表了一篇文章，研究线粒体代谢在化疗反应中的作用并探索CPI-613联合大剂量阿糖胞苷和米托蒽醌治疗复发或耐药急性髓系白血病的最大耐受剂量（MTD），有效性和安全性。

CPI-613可以抑制PDH和α-KGDH，在髓系恶性疾病中具有治疗活性。CLIN CANCER RES近期发表了一篇文章，研究线粒体代谢在化疗反应中的作用并探索CPI-613联合大剂量阿糖胞苷和米托蒽醌治疗复发或耐药急性髓系白血病的最大耐受剂量（MTD），有效性和安全性。

作者在细胞系和动物模型中研究线粒体对化疗的反应。在复发或耐药急性髓系白血病患者中进行CPI-613联合阿糖胞苷和米托蒽醌的Ⅰ期临床试验。研究结果表明，化疗暴露会诱导线粒体PDH依赖的氧摄取。CPI-613使得急性髓系白血病细胞对化疗敏感，表明线粒体代谢是耐药的原因之一。缺少p53不改变对CPI-613的反应。Ⅰ期临床试验纳入67例患者，62例可以评估反应。总反应率为50%。中位生存期为6.7个月。60岁以上的患者CR/CRi率为47%，中位生存期为6.9个月。细胞遗传学风险低的患者反应率达到46%（11/24）。对一些骨髓样本进行基线RNA测序分析发现有治疗反应的患者的一个基因表达特征与治疗前骨髓中B细胞存在相符合。

文章最后认为，化疗联合CPI-613是年龄较大的患者及细胞遗传学风险低的患者的理想治疗方式。

原始出处：
Timothy S.Pardee,Rebecca G.Anderson,et al.A Phase ⅠStudy of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.CLIN CANCER RES.May 2018 doi:10.1158/1078-0432.CCR-17-2282

本文系williamhill asia 医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于williamhill asia 医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章，或“williamhill asia 号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系，williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1783800, encodeId=407e1e83800bc, content=<a href='/topic/show?id=b5b15166c2' target=_blank style='color:#2F92EE;'>#CPI-613#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5166, encryptionId=b5b15166c2, topicName=CPI-613)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Wed Mar 06 09:45:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822063, encodeId=daa31822063aa, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Aug 17 04:45:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314779, encodeId=09c3314e798c, content=好好学习认真学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun May 13 18:42:42 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578681, encodeId=071d15e86813c, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Fri May 11 11:45:00 CST 2018, time=2018-05-11, status=1, ipAttribution=)]
    2019-03-06 swallow

    #CPI-613#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1783800, encodeId=407e1e83800bc, content=<a href='/topic/show?id=b5b15166c2' target=_blank style='color:#2F92EE;'>#CPI-613#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5166, encryptionId=b5b15166c2, topicName=CPI-613)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Wed Mar 06 09:45:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822063, encodeId=daa31822063aa, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Aug 17 04:45:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314779, encodeId=09c3314e798c, content=好好学习认真学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun May 13 18:42:42 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578681, encodeId=071d15e86813c, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Fri May 11 11:45:00 CST 2018, time=2018-05-11, status=1, ipAttribution=)]
    2018-08-17 fangcong

    #髓系白血病#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1783800, encodeId=407e1e83800bc, content=<a href='/topic/show?id=b5b15166c2' target=_blank style='color:#2F92EE;'>#CPI-613#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5166, encryptionId=b5b15166c2, topicName=CPI-613)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Wed Mar 06 09:45:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822063, encodeId=daa31822063aa, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Aug 17 04:45:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314779, encodeId=09c3314e798c, content=好好学习认真学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun May 13 18:42:42 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578681, encodeId=071d15e86813c, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Fri May 11 11:45:00 CST 2018, time=2018-05-11, status=1, ipAttribution=)]
    2018-05-13 zwjnj2

    好好学习认真学习天天学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1783800, encodeId=407e1e83800bc, content=<a href='/topic/show?id=b5b15166c2' target=_blank style='color:#2F92EE;'>#CPI-613#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5166, encryptionId=b5b15166c2, topicName=CPI-613)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Wed Mar 06 09:45:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822063, encodeId=daa31822063aa, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Aug 17 04:45:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314779, encodeId=09c3314e798c, content=好好学习认真学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun May 13 18:42:42 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578681, encodeId=071d15e86813c, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Fri May 11 11:45:00 CST 2018, time=2018-05-11, status=1, ipAttribution=)]
    2018-05-11 ms7899726347904398

    #大剂量#

    0

相关威廉亚洲官网

Haematologica：新诊断AML的老年患者：三种疗法一较高下

2018年1月，美国、加拿大和英国科学家在《Haematologica》发表了新诊断为急性髓系白血病（AML）的65岁或以上患者使用连续高剂量来那度胺、序贯阿扎胞苷和来那度胺或阿扎胞苷的随机研究。

徐兵教授：老年急性髓系白血病的治疗策略

老年急性髓系白血病发生率高，疗效欠佳，死亡率高、生存率极差，是临床研究的难点和热点。厦门大学附属第一医院血液科徐兵教授系统梳理了影响老年急性髓系白血病的预后因素，目前治疗新发老年急性髓系白血病诱导治疗和巩固治疗策略，阐述了难治复发老年急性髓系白血病的治疗方案及新药进展。

Lancet haemat：BP1001，Grb2的反义寡核苷酸，用于难治性/复发性恶性血液病的疗效和安全性评估

在白血病中常见酪氨酸激酶的激活性突变。致癌的酪氨酸激酶利用生长因子受体结合蛋白（Grb2）进行信号转导，从而激活丝裂原活化型蛋白激酶（MAPK）1和MAPK3（ERK2和ERK1）。Maro Ohanian等人推测抑制Grb2可抑制ERK1和ERK2激活、抑制白血病进展。研究人员设计了一种可阻滞Grb2表达的反义寡核苷酸，BP1001，来抑制Grb2，并对其进行相关试验，1期试验结果于近期发表在L

Blood：LSD1抑制剂通过重校正PU.1和C/EBPα依赖的增强子发挥其抗白血病效应

表观遗传调控在急性髓系白血病（AML）中常出现突变和异常表达。抑制染色体修饰酶——如组蛋白去甲基化酶赖氨酸特异性去甲基化酶1（LSD1）和组蛋白甲基化转移酶DOT1L——的靶向治疗，开发为用于治疗难治性疾病的新型疗法。这些靶向制剂的共同特点是可诱导髓系分化，提示在髓系基因程序性表达过程中可以应用多种途径来缓解AML中一致看到的分化阻滞。研究人员利用两种独特而有效的分化诱导性靶向表观遗传疗法（LSD

Blood：在FLT3ITD急性髓系白血病中，FLT3酪氨酸激酶抑制剂处理可暴露谷氨酰胺水解的代谢依赖性

中心点：FLT3ITD酪氨酸激酶（TK）抑制剂在不影响谷氨酰胺代谢的情况下，抑制糖酵解和葡萄糖利用。FLT3 TK活性的靶点和谷氨酰胺代谢相结合，可降低体内外FLT3ITD突变细胞的白血病致病潜能。摘要：FLT3内部串联重复（FLT3ITD）是急性髓系白血病（AML）的常见突变，与患者预后差相关。尽管新一代的FLT3酪氨酸激酶抑制剂（TKI）显现出客观的结果，但FLT3ITD的AML患者的预后仍不

Lancet haemat：用罗米司亭治疗血小板减少的低风险的骨髓增生异常综合征，进展成急性髓系白血病的风险追踪

针对骨髓增生异常综合症患者，治疗血小板减少的有效方法仍是匮乏。在之前报道的一随机2期研究（样本量250）中，用罗米司亭治疗国际预后评分（IPSS）评定的低风险骨髓增生异常综合征可减少血小板的输注量（p<0.0001），增加血液学血小板改善率（p<0.0001）。但该研究因为潜在进展成急性髓系白血病的风险而终止。该研究为随访长达5年的多中心的、双盲的II期临床试验，在多个国家招募18-9